Research article

Assessment of serum interleukin 19 level in patients with warts

  • Received: 13 September 2022 Revised: 08 December 2022 Accepted: 20 December 2022 Published: 12 January 2023
  • Background: Warts are viral cutaneous infections caused by human papilloma virus (HPV), presented by verrucous growth over the skin surface. The cell mediated immune response is considered to play a crucial role in HPV clearance. The viral load and number of lesions increase when there is an imbalance between the T-helper 1 and T-helper 2 immune responses. Interleukin (IL)-19 is a cytokine that belongs to interleukin 10 cytokines family and constitutes a sub-family with IL-20, IL-22 and IL-24. IL-19 is mainly produced by activated monocytes and to a lesser extent by B-cells, keratinocytes and fetal membranes. IL-19 was found to shift T-cell maturation away from the pro-inflammatory T-helper 1 cells toward the anti-inflammatory T-helper 2 cells. It induces IL-4 and IL-13 production in T cells and apoptosis in monocytes. Aim: This study aimed to measure serum level of IL-19 in patients with warts compared to healthy controls and to find out the correlation between this level and number, size and clinical types of warts. Methods: The study included 50 patients with warts and 50 control subjects. Serum concentration of IL-19 was measured by enzyme-linked immune sorbent assay. Results: Interleukin-19 serum level was significantly lower in patients with warts than in controls (P < 0.003). Moreover, there was a significant positive correlation between IL-19 serum level and the number of warts (P = 0.027). Conclusion: Serum level of IL-19 was significantly lower in patients with warts, and this low level might be crucial for an effective cell mediated immunological response to HPV.

    Citation: Radwa El-Sayed Mahmoud Marie, Aya Mohamed kamal Lasheen, Hebat-Allah Hassan Nashaat, Mona A. Atwa. Assessment of serum interleukin 19 level in patients with warts[J]. AIMS Molecular Science, 2023, 10(1): 1-10. doi: 10.3934/molsci.2023001

    Related Papers:

    [1] Archana M Navale, Vanila Devangan, Arpit Goswami, Vikas Sahu, Lavanya S, Devanshu Patel . Effects of pre-existing metformin therapy on platelet count, serum creatinine, and hospitalization in COVID-19 patients with diabetes mellitus. AIMS Molecular Science, 2023, 10(4): 311-321. doi: 10.3934/molsci.2023018
    [2] Marwa M. Esawy, Amir Abd-elhameed, Alshimaa L. Abdallah, Maha E. Alsadik, Elsayed S. Abd elbaser, Marwa A. Shabana, Rania M. Abdullah . Long noncoding RNA HULC is an independent predictor of COVID-19 severity and mortality in relation to microRNA-9 and IL-6. AIMS Molecular Science, 2022, 9(2): 79-90. doi: 10.3934/molsci.2022005
    [3] Amrit Krishna Mitra . Familiar fixes for a modern malady: a discussion on the possible cures of COVID-19. AIMS Molecular Science, 2020, 7(3): 269-280. doi: 10.3934/molsci.2020012
    [4] Sohrab Najafipour, Abdolreza karami, Manoochehr Rasouli, Mehdi Kalani, Seyed-Jalal-Aldin Ashraf-Mansoori, Ali Moravej . Association of interleukin-2 gene variants (positions +114 and −384) and susceptibility to brucellosis in Iranian population. AIMS Molecular Science, 2017, 4(1): 103-109. doi: 10.3934/molsci.2017.1.103
    [5] Amir Khodavirdipour, Fariba Keramat, Seyed Hamid Hashemi, Mohammad Yousef Alikhani . SARS-CoV-2; from vaccine development to drug discovery and prevention guidelines. AIMS Molecular Science, 2020, 7(3): 281-291. doi: 10.3934/molsci.2020013
    [6] Mohamad S. Hakim, Xinying Zhou, Yijin Wang, Maikel P. Peppelenbosch, Qiuwei Pan . Anti-diabetic drugs, insulin and metformin, have no direct interaction with hepatitis C virus infection or anti-viral interferon response. AIMS Molecular Science, 2014, 1(1): 49-58. doi: 10.3934/molsci.2014.1.49
    [7] Ahmed Yaqinuddin, Abdul Hakim Almakadma, Junaid Kashir . Kawasaki like disease in SARS-CoV-2 infected children – a key role for neutrophil and macrophage extracellular traps. AIMS Molecular Science, 2021, 8(3): 174-183. doi: 10.3934/molsci.2021013
    [8] Mohd Shukri Abd Shukor, Mohd Yunus Abd Shukor . Molecular docking and dynamics studies show: Phytochemicals from Papaya leaves extracts as potential inhibitors of SARS–CoV–2 proteins targets and TNF–alpha and alpha thrombin human targets for combating COVID-19. AIMS Molecular Science, 2023, 10(3): 213-262. doi: 10.3934/molsci.2023015
    [9] Vittorio Emanuele Bianchi, Giancarlo Falcioni . Reactive oxygen species, health and longevity. AIMS Molecular Science, 2016, 3(4): 479-504. doi: 10.3934/molsci.2016.4.479
    [10] Amal Feiroze Farouk, Areez Shafqat, Shameel Shafqat, Junaid Kashir, Khaled Alkattan, Ahmed Yaqinuddin . COVID-19 associated cardiac disease: Is there a role of neutrophil extracellular traps in pathogenesis?. AIMS Molecular Science, 2021, 8(4): 275-290. doi: 10.3934/molsci.2021021
  • Background: Warts are viral cutaneous infections caused by human papilloma virus (HPV), presented by verrucous growth over the skin surface. The cell mediated immune response is considered to play a crucial role in HPV clearance. The viral load and number of lesions increase when there is an imbalance between the T-helper 1 and T-helper 2 immune responses. Interleukin (IL)-19 is a cytokine that belongs to interleukin 10 cytokines family and constitutes a sub-family with IL-20, IL-22 and IL-24. IL-19 is mainly produced by activated monocytes and to a lesser extent by B-cells, keratinocytes and fetal membranes. IL-19 was found to shift T-cell maturation away from the pro-inflammatory T-helper 1 cells toward the anti-inflammatory T-helper 2 cells. It induces IL-4 and IL-13 production in T cells and apoptosis in monocytes. Aim: This study aimed to measure serum level of IL-19 in patients with warts compared to healthy controls and to find out the correlation between this level and number, size and clinical types of warts. Methods: The study included 50 patients with warts and 50 control subjects. Serum concentration of IL-19 was measured by enzyme-linked immune sorbent assay. Results: Interleukin-19 serum level was significantly lower in patients with warts than in controls (P < 0.003). Moreover, there was a significant positive correlation between IL-19 serum level and the number of warts (P = 0.027). Conclusion: Serum level of IL-19 was significantly lower in patients with warts, and this low level might be crucial for an effective cell mediated immunological response to HPV.


    Abbreviations

    IL:

    Interleukin; 

    HPV:

    Human papilloma virus; 

    TH:

    T-helper; 

    ELISA:

    Enzyme-Linked Immune-sorbent Assay; 

    HRP:

    Horseradish Peroxidase; 

    OP:

    optical density; 

    HBV:

    Hepatitis B virus

    Warts are common benign tumors caused by human papillomavirus (HPV) infection. Warts are classified into common warts (verruca vulgaris), plane warts (verruca plana), plantar warts and genital warts (condyloma acuminatum) [1]. HPV infections, in most cases, are self-limiting and can be eradicated by an effective cell-mediated immune response. High-risk HPV types are capable of shifting immune response from T-helper (TH) 1 to TH2 which enhances disease progression [2].

    Interleukin (IL)-19 is expressed in immune cells such as stimulated and naive monocytes, activated and naive B cells and non-immune cells such as epithelial cells and keratinocytes [3]. IL-19 signaling is mediated by IL-20 receptors expressed in non-immune cells such as keratinocytes and in immune cells including natural killer cells, monocytes, B cells and T cells [4]. IL-19 administration was found to shift T cell maturation away from the pro-inflammatory TH1 cells and toward the anti-inflammatory TH2 cells. It induces IL-4 and IL-13 and decreases interferon-gamma production in T cells [5].

    Considering the lack of prior studies that have investigated IL-19 expression in HPV infection, this study aimed to evaluate the serum level of IL-19 in patients with warts compared to control subjects to highlight its possible role in the immunological response to HPV infection.

    Fifty patients with warts and 50 healthy controls participated in this case control study. Patients were selected from the Dermatology Outpatient Clinic at Suez Canal University Hospital, Ismailia, Egypt. The clinical pathology laboratory executed the laboratory tests. The Institutional Review Board and the Research Ethics Committee, Faculty of Medicine, Suez Canal University, both provided their approval to the study on the first of July 2020 with the approval number 4217. Age and sex matched healthy control participants who had no history of autoimmune diseases, malignancy, asthma or allergic skin conditions were prospectively recruited from blood donors. To participate in the study, every participant signed a written informed consent. The researchers identified warts by examining for hard verrucous papules or verrucous endophytic proliferation (palmoplantar warts). All patients underwent history-taking and dermatological examination that included an inspection of their mucosal surfaces, periungual areas, genital and perianal areas with an emphasis on the site, number, disease duration and clinical type of warts as well as whether the warts had developed for the first time or had returned following prior treatment.

    Each participant in the study had five milliliters of venous blood drawn from their peripheral veins and placed in sterile serum separator tubes. The samples were centrifuged at a speed of 3000 rpm for 20 minutes following a 20-minute incubation period at room temperature. After being separated, the serum was put into storage at −20 °C until use. Enzyme-Linked Immune-sorbent Assay (ELISA) was used to measure the level of Interleukin 19 in serum using a commercial IL-19 ELISA Kit (catalog number: SL1906Hu; Sun Long Biotech, China; sensitivity: 0.8 pg/ml; range of assay: 3.3 pg/ml – 200 pg/ml). The technique utilized in this kit was Sandwich-ELISA. An antibody specific to Interleukin 19 had been pre-coated on the Micro Elisa strip plate included in this kit. Standards or samples were added to the wells. Then, each sample received a Horseradish Peroxidase (HRP)-conjugated antibody specific for IL-19. Then, each Micro Elisa strip plate well received an addition of an antibody specific for IL-19 that had been HRP-conjugated. Free parts were removed by washing. Each well was filled with the tetramethylbenzidine substrate solution. Only the wells containing IL-19 and HRP-conjugated IL-19 antibody displayed blue coloration before changing to yellow once the stop solution was added. Spectrophotometric measurements of the optical density (OD) were made at a wavelength of 450 nm. The OD value is correlated with the level of IL-19. By comparing the samples' OD to the standard curve, it was possible to determine the amount of IL-19 present in each sample.

    Statistical Package for the Social Sciences version 20.0 software was used to analyze the data (Armonk, NY: IBM Corp.). Number and percent were used to describe qualitative data. The normality of the distribution was confirmed using the Kolmogorov-Smirnov test. The range (minimum and maximum), mean, standard deviation, median and interquartile range were used to characterize quantitative data. Student's t-test and Mann Whitney tests for quantitative variables with normal distribution, the Kruskal Wallis test for quantitative variables with abnormal distribution, the Chi-squared test for categorical variables and Spearman's correlation were used. Result significance was assessed at a 5% level of confidence (P < 0.05).

    Thirty-two (64%) patients were females, and 18 patients were males (36%). The mean of patients' age was 31.32 ± 14.48 years (range 5 to 65 years). Twenty-three control participants were female (46%) while 27 were males (54%). The mean age of control participants was 27.60 ± 7.28 years (range 8 to 47years). There was no statistically significant difference in age or sex between patients and controls (Table 1).

    Table 1.  Demographics of patients with warts (n = 50) and healthy control participants (n = 50).
    Patients with warts (n = 50)
    Controls (n = 50)
    Test of Sig. p
    No. % No. %
    Gender
    Male 18 36.0 27 54.0 χ2 = 3.273 0.070
    Female 32 64.0 23 46.0
    Age (years)
    Min. – Max. 5.0 – 65.0 8.0 – 47.0 T = 1.623 0.109
    Mean ± SD. 31.32 ± 14.48 27.60 ± 7.28
    Median (IQR) 28.0 (21.0 – 37.0) 27.0(25.0 – 31.0)

    Note: χ2: Chi square test; t: Student t-test; Min. – Max.: range; IQR: Interquartile range; SD: standard deviation.

     | Show Table
    DownLoad: CSV

    The mean duration of warts was 21.04 ± 24.60 months (range: 1 – 84 months). The mean number of warts was 10.50 ± 9.47 warts (range: 1 – 40 warts); 42 (84%) patients had multiple warts, compared to 8 (16%) patients who had a single wart. According to the clinical classification of warts, 34 (68%) patients had common warts; of them, 2 (6%) patients had filiform warts, while 7 (21%) patients had periungual warts. Meanwhile, 4 (8%) patients had both plane warts and common warts, compared to 2 (4%) patients who had both palmoplantar and common warts.

    Table 2.  Clinical data of patients with warts (n = 50).
    No. lesions No. %
    Min. – Max. 1.0 – 40.0
    Mean±SD. 10.50 ± 9.47
    Median (IQR) 7.50 (3.0 – 15.0)
    Single wart 8 16.0
    Multiple 42 84.0
    2 – 5 warts 11 22.0
    6 – 10 warts 12 24.0
    11 – 15 warts 7 14.0
    16 – 20 warts 7 14.0
    More than 20 warts 5 10.0
    Single site 40 80.0
    Face 8 16.0
    UL 23 46.0
    LL 2 4.0
    Genital 3 6.0
    Scalp 3 6.0
    Breast 1 2.0
    Multiple site 10 20.0
    Single type 43 86.0
    Common 34 68.0
    Plane 6 12.0
    Genital 3 6.0
    Multiple types 7 14.0
    Palmoplantar, common 2 4.0
    Common, plane 4 8.0
    Genital, common 1 2.0
    Duration (months)
    Min. – Max. 1.0 – 84.0
    Mean ± SD. 21.04 ± 24.60
    Median (IQR) 12.0 (6.0 – 24.0)
    Recurrence
    Primary 26 52.0
    Recurrence after treatment 24 48.0

    Note: UL: Upper limb; LL: Lower limb; Min. – Max.: range; IQR: Interquartile range; SD: standard deviation.

     | Show Table
    DownLoad: CSV

    There were 10 (20%) patients who had warts in multiple body sites, compared to 40 (80%) patients who had warts only in one location; 26 patients (52%) had warts for the first time, while 24 patients (48%) had recurrent warts after previous treatment (Table 2).

    Serum level of IL-19 in patients ranged from 60.0 to 330.0 pg/mL, with a mean of 96.65 ± 53.22 pg/mL, while in control subjects, they ranged from 65.0 to 730.0 pg/mL with a mean of 141.0 ± 142.55 pg/mL (Table 3). Patients with warts had significantly lower serum levels of IL-19 than control participants (P = 0.003) (Figure 1).

    Table 3.  Serum level of IL-19 in patients with warts (n = 50) compared to control participants (n=50).
    IL-19 level (pg/ml) Patients with warts (n = 50) Controls (n = 50) U p
    Min. – Max. 60.0 – 330.0 65.0 – 730.0 817.50* 0.003*
    Mean ± SD. 96.65 ± 53.22 141.0 ± 142.55
    Median (IQR) 85.0 (65.0 – 105.0) 106.25 (80.0 – 125.0)

    Note: U Mann-Whitney test; Min. – Max.: range; IQR: Interquartile range; SD: standard deviation; IL: interleukin; p < 0.05 is considered statistically significant.

     | Show Table
    DownLoad: CSV
    Figure 1.  Serum levels of IL-19 in patients with warts (n = 50) compared to control participants (n = 50).

    Additionally, there was a significant positive correlation between the number of warts and serum level of IL-19 (P = 0.027) (Table 4, Figure 2).

    Table 4.  Correlation between IL-19 serum level and clinical data of patients with warts (n=50).
    IL-19 serum level (pg/ml)
    rs p
    Age −0.161 0.265
    Number of warts 0.314 0.027*
    Duration (months) 0.215 0.134

    Note: rs: Spearman coefficient; IL: interleukin; p < 0.05 is considered statistically significant.

     | Show Table
    DownLoad: CSV
    Figure 2.  Correlation between serum level of IL-19 and the number of warts in enrolled patients (n = 50).

    On the other hand, there was no relation between IL-19 serum level and other clinical data of patients with warts (Table 5).

    Approximately 50% of HPV infections resolve in six months due to effective cell-mediated immune response, and in around 90% of cases the virus become undetectable within 5–7 years [6]. Recent research contradicts the theory of virus clearance. Since virus reactivation is common among immune-compromised patients, there is a doubt that the virus is indeed cleared. It is rather conclusive that it is under good immune control, giving rise to undetectable viral load or latency [7].

    Many immunological mechanisms interact in the process of virus clearance, including innate and adaptive immunity. Although these mechanisms are highly effective, the virus has developed multiple counteracting mechanisms to fight the immune response, ultimately leading to virus persistence or rather latency. Moreover, the virus has developed mechanisms that can take over the immune system, creating a chronic pro-inflammatory state advancing to carcinogenesis and tumor progression [6],[7].

    Table 5.  Relation between IL-19 serum level and clinical data of patients with warts (n=50).
    N IL-19 serum level (pg/ml)
    Test of Sig. p
    Min. – Max. Mean ± SD. Median
    Gender
    Male 18 60.0 – 145.0 95.28 ± 26.65 95.0 U = 219.50 0.164
    Female 32 60.0 – 330.0 97.42 ± 63.92 75.0
    Site
    Single 40 60.0 – 330.0 97.44 ± 57.16 85.0 U = 195.0 0.914
    Multiple 10 60.0 – 145.0 93.50 ± 35.28 82.50
    Single site
    Face 8 70.0 – 135.0 104.38 ± 24.85 107.50 H = 5.252 0.262
    UL 23 60.0 – 330.0 100.11 ± 73.54 75.0
    LL 2 70.0 – 95.0 82.50 ± 17.68 82.50
    Genital 3 65.0 – 100.0 83.33 ± 17.56 85.0
    Scalp 3 65.0 – 105.0 81.67 ± 20.82 75.0
    Breast 1# 100.0
    Single type
    Common 34 60.0 – 330.0 95.81 ± 62.20 72.50 H = 3.311 0.191
    Plane 6 70.0 – 135.0 104.17 ± 28.18 105.0
    Genital 3 65.0 – 100.0 83.33 ± 17.56 85.0
    Multiple types
    Palmoplantar, common 2 75.0 – 90.0 82.50 ± 10.61 82.50 U = 2.0 0.533
    Common, plane 4 60.0 – 140.0 110.0 ± 38.30 120.0
    Genital, common 1# 95.0
    Recurrence
    Primary 26 60.0 – 330.0 102.60 ± 68.48 90.0 U = 304.50 0.884
    Recurrence after treatment 24 60.0 – 145.0 90.21 ± 29.21 80.0

    Note: U: Mann Whitney test; H: Kruskal Wallis test; LL: Lower limb; UL: Upper limb; Min. – Max.: range; IQR: Interquartile range; SD: standard deviation; IL: Interleukin.

     | Show Table
    DownLoad: CSV

    Interleukin-19 belongs to interleukin 10 cytokines family and constitutes a sub-family with IL-20, IL-22 and IL-24. IL-19 was shown to stimulate the production of anti-inflammatory TH2 cytokine in T lymphocytes in a positive feedback loop, increasing IL-4-positive and decreasing interferon γ-positive lymphocytes [8].

    Little is known about the biological effects of IL-19, particularly in viral infections. To date, this is the first study to evaluate serum level of IL-19 in patients with warts. This study showed a significant decrease in IL-19 concentration in the sera of patients with warts in comparison with controls. IL-19 stimulates mainly TH2 anti-inflammatory immune response [5], whereas the immune response to HPV infection relies mainly on TH1 and cytotoxic T cells [9]. As all the enrolled patients were immune-competent, the low level of IL-19 might indicate an attempt of the immune system to maintain effective TH1 cell mediated immune response in order to eradicate HPV and depress its transmission. This low IL-19 level, however, was inadequate to elicit a significant TH1 immune response capable of eradicating HPV infection. The study also found that IL-19 level was positively correlated with the number of warts. Thus, patients with multiple warts had higher levels of IL-19 than patients with single or fewer warts, but their IL-19 levels remained lower than healthy controls. This elevated level in patients with multiple warts might have shifted the immune response slightly towards the TH2 profile, leading to increased viral load and multiplicity of lesions.

    Notably, studies with polyI:C, a synthetic RNA analogue that resembles viral RNA and induces the synthesis of type 1 interferon and inflammatory mediators, indicated that in IL-19 defective mice, the production of several mediators was increased. Among them are IL-6, IL-12, CCL5, CCL2 and CXCL1. CCL2 and CCL5 are chemokines that play critical roles in viral infection by activating natural killer cells. The authors concluded that IL-19 could interfere with host defense mechanisms for viral infections by suppressing the release of mediators in response to polyI:C [10].

    Interestingly, previous studies reported that IL-19 administration induced cell apoptosis via enhancing tumor necrosis factor-a production and that blockage of its receptors reversed its apoptotic effects [11],[12]. IL-19 low level may therefore contribute to epidermal hyperplasia encountered in HPV infections.

    Interleukin-17 serum level was observed to be lower in patients with recalcitrant warts than in control subjects [13]. Interestingly, IL-17 was found to enhance the production of IL-19 in keratinocytes [14]. Low IL-17 level in patients with warts is consistent with our finding of low IL-19 level.

    Interleukin-10, whose gene is structurally similar to the IL-19 gene and is located head to head with the IL-19 gene, was investigated in HPV infections. In the presence of HPV oncoproteins, IL-10 was found to function as an anti-inflammatory agent and was highly expressed in tumor cells, and its expression was directly proportional to the development of HPV-positive cervical cancer [15]. Additionally, cervical cancer cells transfected to express the HPV E2 protein induce elevated levels of IL-10 messenger RNA in HPV-infected cells. The elevated expression of IL-10 may allow for virus persistency, the transformation of cervical epithelial cells and consequently cancer development [16].

    Interleukin-22, another cytokine from the IL-10 family, has previously been assessed in patients with warts. IL-22 serum level in patients with warts was significantly greater than in control subjects and correlated positively with the number of warts. Patients with recurring warts following prior treatment exhibited significantly higher levels than those with newly developing warts. IL-22, a proinflammatory cytokine, may be involved in the immunological response to HPV by enhancing keratinocyte production of anti-microbial peptides [17].

    Studies with larger sample size assessing tissue expression of IL-19 in patients with warts, investigating its serum level and tissue expression before and after wart treatment by different modalities and detecting IL-19 gene polymorphism in patients with warts, especially recalcitrant warts, are recommended. Further prospective studies that compare IL-19 serum level in patients with spontaneous resolution of warts or warts responding to treatment versus patients with recalcitrant warts are recommended to confirm the role of IL-19 in the immune response to HPV.

    Serum IL-19 level was significantly lower in patients with warts, and this low level might have a possible role in enhancing the cell-mediated immune response against HPV infections.



    Conflicts of Interest



    All authors declare no conflicts of interest in this paper.

    [1] Paaso A, Koskimaa HM, Welters MJ, et al. (2015) Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years. J Transl Med 13: 1-11. https://doi.org/10.1186/s12967-015-0498-9
    [2] Steinbach A, Riemer AB (2018) Immune evasion mechanisms of human papillomavirus. Int J Cancer 142: 224-229. https://doi.org/10.1002/ijc.31027
    [3] Fujimoto Y, Azuma YT, Matsuo Y, et al. (2017) Interleukin-19 contributes as a protective factor in experimental Th2-mediated colitis. Naunyn. Schmiedebergs. Arch Pharmacol 390: 261-268. https://doi.org/10.1007/s00210-016-1329-0
    [4] Sabat R (2010) IL-10 family of cytokines. Cytokine Growth Factor Rev 21: 315-324. https://doi.org/10.1016/j.cytogfr.2010.11.001
    [5] Gallagher G, Eskdale J, Jordan W, et al. (2004) Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 4: 615-626. https://doi.org/10.1016/j.intimp.2004.01.005
    [6] Schiffman M, Doorbar J, Wentzensen N, et al. (2016) Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2: 16086. https://doi.org/10.1038/nrdp.2016.86
    [7] Fernandes JV, DE Medeiros Fernandes TA, DE Azevedo JC, et al. (2015) Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol Lett 9: 1015-1026. https://doi.org/10.3892/ol.2015.2884
    [8] Liao SC, Cheng YC, Wang YC, et al. (2004) IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol 173: 6712-6718. https://doi.org/10.4049/jimmunol.173.11.6712
    [9] Oguejiofor K, Hall J, Slater C, et al. (2015) Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. Br J Cancer 113: 886-893. https://doi.org/10.1038/bjc.2015.277
    [10] Azuma YT, Nishiyama K (2020) Interleukin-19 enhances cytokine production induced by lipopolysaccharide and inhibits cytokine production induced by polyI:C in BALB/c mice. J Vet Med Sc 82: 891-896. https://doi.org/10.1292/jvms.20-0137
    [11] Liao YC, Liang WG, Chen FW, et al. (2002) IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol 169: 4288-4297. https://doi.org/10.4049/jimmunol.169.8.4288
    [12] Hsu YH, Li HH, Sung JM, et al. (2013) Interleukin-19 mediates tissue damage in murine ischemic acute kidney injury. PLoS One 8: e56028. https://doi.org/10.1371/journal.pone.0056028
    [13] AH, Esawy AM, Khalifa NA, et al. (2020) Evaluation of serum interleukin 17 and zinc levels in recalcitrant viral wart. J Cosmet Dermatol 19: 954-959. https://doi.org/10.1111/jocd.13106
    [14] Xu X, Prens E, Florencia E, et al. (2021) Interleukin-17A Drives IL-19 and IL-24 Expression in Skin Stromal Cells Regulating Keratinocyte Proliferation. Front Immunol 12: 719562. https://doi.org/10.3389/fimmu.2021.719562
    [15] Wang Y, Liu X, Li Y, et al. (2013) The paradox of IL-10-mediated modulation in cervical cancer (Review). Biomedical Reports 1: 347-351. https://doi.org/10.3892/br.2013.69
    [16] Berti FCB, Pereira APL, Cebinelli GCM, et al. (2017) The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma. Cytokine Growth Factor Rev 34: 1-13. https://doi.org/10.1016/j.cytogfr.2017.03.002
    [17] Marie REM, Abuzeid AQEM, Attia FM, et al. (2021) Serum level of interleukin-22 in patients with cutaneous warts: A case-control study. J Cosmet Dermatol 2021: 1782-1787. https://doi.org/10.1111/jocd.13779
  • This article has been cited by:

    1. Clara Matei, Laura Sorina Diaconu, Mircea Tampa, Interleukins in the Pathogenesis of Warts: Insight from the Last Decade—A Narrative Review, 2025, 14, 2077-0383, 2057, 10.3390/jcm14062057
  • Reader Comments
  • © 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(2076) PDF downloads(130) Cited by(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog